Free Trial

Solid Biosciences (SLDB) Stock Price, News & Analysis

Solid Biosciences logo
$5.90 +0.16 (+2.79%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$5.91 +0.01 (+0.24%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Solid Biosciences Stock (NASDAQ:SLDB)

Advanced

Key Stats

Today's Range
$5.75
$6.01
50-Day Range
$5.00
$7.07
52-Week Range
$2.41
$7.37
Volume
1.19 million shs
Average Volume
1.25 million shs
Market Capitalization
$459.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Moderate Buy

Company Overview

Solid Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

SLDB MarketRank™: 

Solid Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 475th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Solid Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Solid Biosciences has a consensus price target of $15.00, representing about 154.2% upside from its current price of $5.90.

  • Amount of Analyst Coverage

    Solid Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Solid Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Solid Biosciences are expected to grow in the coming year, from ($2.84) to ($2.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Solid Biosciences is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Solid Biosciences is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Solid Biosciences has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Solid Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    17.04% of the float of Solid Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Solid Biosciences has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Solid Biosciences has recently increased by 0.91%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Solid Biosciences does not currently pay a dividend.

  • Dividend Growth

    Solid Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.04% of the float of Solid Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Solid Biosciences has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Solid Biosciences has recently increased by 0.91%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Solid Biosciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Solid Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    61 people have searched for SLDB on MarketBeat in the last 30 days. This is an increase of 455% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Solid Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.63% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Solid Biosciences' insider trading history.
Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLDB Stock News Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
See More Headlines

SLDB Stock Analysis - Frequently Asked Questions

Solid Biosciences' stock was trading at $4.00 on January 1st, 2025. Since then, SLDB shares have increased by 47.5% and is now trading at $5.90.

Solid Biosciences Inc. (NASDAQ:SLDB) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

Shares of Solid Biosciences reverse split on Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Solid Biosciences (SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/12/2025
Today
10/05/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLDB
CIK
1707502
Fax
N/A
Employees
100
Year Founded
2013

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+154.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.70 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.70%
Return on Assets
-56.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.34
Quick Ratio
9.34

Sales & Book Value

Annual Sales
$8.09 million
Price / Sales
56.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.43 per share
Price / Book
1.72

Miscellaneous

Outstanding Shares
77,870,000
Free Float
76,389,000
Market Cap
$459.43 million
Optionable
Optionable
Beta
2.53

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:SLDB) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners